It’s called ibrutinib, and it’s a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy. In research published in ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia, or CLL, by combining its oncology drug Venclexta with another cancer-fighting drug. The North Chicago-based drugmaker has filed a ...

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

A phase 3, randomized, open-label trial enrolled 535 patients who were randomly assigned 1:1:1 to receive acalabrutinib-obinutuzumab (n = 179), acalabrutinib monotherapy (n = 179), or ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...

The effectiveness of a leukemia drug from Terns Pharmaceuticals exceeded the hopes of many doctors and investors when the biotech firm reported early phase trial results this week. Terns shares jumped ...